CCT241736

Overview

CCT241736 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A K d , 7.5 nM, IC 50 , 38 nM; Aurora-B K d , 48 nM), FLT3 kinase ( K d , 6.2 nM), and FLT3 mutants including FLT3-ITD ( K d , 38 nM) and FLT3 (D835Y) ( K d , 14 nM).

Application

Products | Products > Disease Areas > Blood Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > FLT3 | Products > Signaling Pathways > Aurora Kinase

Product Information

• Catalog No.: HY-18161
• CAS No.: 1402709-93-6
• Molecular Formula: C22H23Cl2N7
• Molecular Weight: 456.37
• Purity: 99.88%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 2.5 mg/mL (5.48 mM); Suspended solution; Need ultrasonic and warming
• Availability: In-stock

Source

Original product source